To further assess whether pharmacological NR1D1 activation could improve muscle function in a pathological DMD model in vivo, mdx/Utr+/– mice, which closely recapitulate the features of the human disease, were daily injected with SR9009 for 20 days. This evidence concerns the gene NR1D1 and Duchenne muscular dystrophy.